PP168—A Survey on a Clinical Research Information Portal Site for the General Public in Japan  by Arita, E. et al.
Poster Presentation Abstracts
2013 e71
nonlinear PK, DDI related changes in clearance, and absolute bio-
availability/mass balance data.
Conclusion: This integrated study design is a highly efficient mecha-
nism for generating definitive intravenous pharmacokinetic, clear-
ance, absolute bioavailability, mass balance, and human metabolism 
data from a single radiolabeled clinical protocol.
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Introduction: In recent years, improvement efforts have been geared 
toward activating clinical research performed in Japan. However, 
objectives of clinical research and trials are often unclear to the 
general public, given the difficulty in obtaining appropriate infor-
mation. To gain access to appropriate information about clinical 
research and trials, the general public needs information tools that 
are easy to use, as well as a basic knowledge about clinical research 
and trials. Building an efficient and easy-to-use portal site for patients 
and citizens is a major component of the new “5-year Clinical Trial 
Activation Plan (2012).” The present study aimed to investigate the 
type of information required and the kind of portal site considered 
useful by the general public based on a questionnaire survey.
Patients (or Materials) and Methods: Subjects of this study included 
500 Internet users aged ≥ 20 years. We used an Internet research 
method. The period of internet research from December 10, 2012, 
to December 20, 2012.The survey questionnaire mainly consisted of 
the following 3 parts:
1.  What kind of information do you want to obtain from a “clini-
cal research (trials) information site”?
2.  Ideas and wishes helpful for improving the information site 
(free-style questions)
3.  What kind of tools do you find easy to use when accessing the 
information site?
This study was carried out as part of the study funded by Grant-
in-Aid for Scientific Research of Health, Labour and Welfare in 
2012 FY. The study protocol was approved by the Kitasato Institute 
Hospital Research Ethics Committee.
Results: 1. The clinical research information which they considered 
highly necessary were “purpose,” “method,” “risks by participat-
ing,” “compensation if there is a health hazard,” “inconvenience or 
danger,” “cost,” and “period.”
2. Survey results showed that a site that allows the user to quickly 
extract only what is relevant to him/her was desired (eg, “I can search 
if I put the name of disease and symptoms,” “I want to be able to 
search by region,””Iwant a visualfriendly site”), in addition to “ease 
of access,” “explicit basis of reliability,” and “use of plain vocabulary.”
3. More than 90% responded that they use a personal computer 
(PC) at home to access the Internet. Use of a smartphone was < 30%, 
with the percentage being higher in younger respondents than older 
respondents. While > 60% of people used a PC for a longer time 
period than they used a smartphone, people in their 20s and 30s 
used a smartphone longer. While use of the social networking site 
(SNS) has spread recently, as a whole, it remained at 9.8%, except 
in the 20s (30%).
Conclusion: While building a web portal as a means to provide 
appropriate information is necessary, it is also important to increase 
the basic knowledge of clinical research and trials in the general pub-
lic so that they can determine the appropriateness of the information 
available to them.
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Introduction: The treatment modalities of ucerative colitis is an 
unmate need. The present study aims to evaluate efficacy of piogl-
itazone in mild to moderate ulcerative colitis patients compared with 
placebo. Previous studies were reportedly done on rosiglitazone, 
and this is foremost study to evaluate the efficacy of pioglitazone in 
ulcerative colitis patients.
Patients (or Materials) and Methods: Total 32 patients were seen 
in the study. It was a randomized, double-blind, placebo-controlled 
clinical trial compared the efficacy of pioglitazone 15 mg or placebo 
orally twice daily for 8 weeks in patients with mild to moderate active 
ulcerative colitis. The first group received 15-mg pioglitazone 2 times 
daily along with mesalamine. Second group received mesalamine plus 
similar looking placebo. The patients were followed up to 8 weeks, 
response to treatment was assessed clinically by Mayo clinical scor-
ing systems. Sigmoidoscopy was done at baseline and at 8 weeks of 
completion of treatment.
Results: Five patients were treated with pioglitazone and 4 patients were 
treated with placebo, completed therapy and achieved primary outcome. 
Gastrointestinal quality of life scores showed significant improvement 
in pioglitazone score compared with placebo group (0.03). Among the 
secondary efficacy end points, therapy with pioglitazone group lead to 
decrease in stool frequency, consistency, blood in stools, and abdominal 
pain. In placebo group the stool frequency decreased from (4.8 [3] to 
2 [1]) at the end of 8 weeks though the stool frequency was higher in 
placebo group initially. During the study, pioglitazone showed edema 
and weight gain and in placebo group, nausea, vomiting, abdominal 
pain, and diarrhea were most commonly observed.
Conclusion: The present double-blinded, placebo-controlled study 
with 8 weeks therapy of pioglitazone was not found superior to 
placebo for induction of clinical response in patients with ulcerative 
colitis.
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Introduction: While bariatric surgery (BS) to combat obesity con-
fers risks, it can also result in remission of diabetes mellitus (DM). 
Clinicians managing such patients should appreciate the relative and 
absolute extents of the latter effect. We therefore set out to derive 
unadjusted values for the relative chance (RC) and number needed 
to treat (NNT) for such an effect.
Patients (or Materials) and Methods: Two recently published, non-
blinded, randomized clinical trials compared DM remission rates 
